CRO BioAgilytix and ATCC sign strategic partnership

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Tsyhun)
(Image: iStock/Tsyhun)

Related tags Contract research organization Biotechnology

ATCC has signed a strategic agreement with the contract research organization (CRO) BioAgilytix as part of its ongoing initiative to provide CRO services.

ATCC in recent years launched a new initiative to provide custom biological-based Contract Research Organization (CRO) services and standards for the life sciences community, with a focus on biotech and pharma​,” Scott Siegel, VP of Corporate Development and Chief Business Officer at ATCC, told

As part of this initiative, Siegel said the partnership with BioAgilytix represents “an important step forward.”

The agreement will span multi-year and involves a co-marketing arrangement across ATCC’s complementary areas of cell biology services.

Specifically, ATCC will offer tool and reagent development and storage services, including custom-engineered cell lines and primary cells to complement BioAgilytix’s assay solutions.

As a 90-year old life sciences institution, it is critical for ATCC to continuously seek ways to evolve and continue our mission of enabling important R&D activities that drive scientific discoveries and advancements​,” Siegel explained.

One of our strategic goals is to develop additional scientifically-relevant products and services, and key to that goal is the expansion of our custom biological-based Contract Research Organization (CRO) services and standards​,” he added.

With this goal in mind, the company evaluated external opportunities in the bioanalytical space and chose BioAgilytix as a partner.

Through the strategic partnership, Seigel explained the companies’ complementary capabilities provide the market with “a total assay solution​” to facilitate “the rapid and efficient development of important new medicines​.”

Additionally, a minority equity investment on the part of ATCC signals the company’s commitment to the relationship and provides the company with a seat on BioAgilytix’s commercial advisory board.

Now that the agreement is signed, Siegel said ATCC is planning a kick-off meeting with BioAgilityix to begin implementing co-marketing plans.

Related topics Preclinical Research

Related news

Show more